Profile data is unavailable for this security.
About the company
Flerie AB, formerly InDex Pharmaceuticals Holding AB, is a Sweden-based company, which is primarily engaged in the healthcare industry. The Company is an active long-term global biotech and pharmaceutical investor that managing a portfolio of companies in Europe, Israel, and the US. Flerie invests in companies across the entire value chain, providing exposure to opportunities across three segments: Product Development, Commercial Growth, and Limited Partnerships. The Product Development segment consists of early-stage biotech and pharma companies in product development. The Commercial Growth segment consists of companies that are already selling products or services and showcasing proof-of-concept with high growth and some that have already reached profitability. The Limited Partnerships segment provides benefits for the other two segments, including co-investment opportunities, and derisks Flerie’s investment portfolio.
- Revenue in SEK (TTM)108.34m
- Net income in SEK-56.48m
- Incorporated2016
- Employees7.00
- LocationFlerie ABSkeppsbron 16STOCKHOLM 111 30SwedenSWE
- Phone+46 812203850
- Fax+46 850884739
- Websitehttps://www.flerie.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Moberg Pharma AB (publ) | 820.00k | -22.56m | 842.10m | 9.00 | -- | 1.33 | -- | 1,026.95 | -1.09 | -1.09 | 0.0379 | 21.63 | 0.0014 | -- | 0.2841 | -- | -3.81 | -- | -3.96 | -- | 60.00 | -- | -2,751.22 | -- | 1.73 | -- | 0.0073 | -- | -100.00 | -- | -34.26 | -- | -- | -- |
Vistin Pharma ASA | 435.59m | 55.88m | 960.66m | 77.00 | 17.19 | 3.25 | 13.05 | 2.21 | 1.27 | 1.27 | 9.88 | 6.70 | 1.11 | 2.31 | 7.44 | 5,692,663.00 | 14.28 | 1.73 | 18.93 | 2.11 | 59.93 | 58.92 | 12.83 | 2.36 | 0.8536 | 32.96 | 0.0934 | -- | 51.35 | 16.95 | 1,066.84 | -- | -0.1922 | -- |
Infant Bacterial Therapeutics AB | 0.00 | -128.42m | 1.28bn | 9.00 | -- | 4.79 | -- | -- | -9.96 | -9.96 | 0.00 | 20.59 | 0.00 | -- | -- | 0.00 | -37.63 | -16.11 | -43.78 | -16.69 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -88.03 | -- | -- | -- |
Photocure ASA | 509.24m | 4.79m | 1.57bn | 102.00 | 332.86 | 3.28 | 47.82 | 3.09 | 0.1755 | 0.1755 | 19.02 | 17.82 | 0.7215 | 0.9144 | 7.93 | 5,024,010.00 | 0.6789 | -3.06 | 0.7682 | -3.54 | 94.65 | 93.64 | 0.941 | -5.15 | 4.33 | -- | 0.00 | -- | 27.35 | 22.50 | 101.36 | -- | 49.83 | -- |
Probi AB | 607.54m | -602.00k | 3.42bn | 167.00 | -- | 2.40 | 35.62 | 5.63 | -0.0528 | -0.0528 | 53.32 | 125.16 | 0.3885 | 3.23 | 6.52 | 3,797,144.00 | -0.0385 | 4.64 | -0.0407 | 4.98 | 32.39 | 42.04 | -0.0991 | 9.83 | 6.22 | -- | 0.0353 | 21.42 | 1.52 | 0.7684 | -58.60 | -26.09 | 31.01 | -- |
Flerie AB | 108.34m | -56.48m | 3.66bn | 7.00 | -- | 1.06 | -- | 33.79 | -0.1037 | -0.1037 | 0.2028 | 0.443 | 0.3559 | -- | -- | 15,477,000.00 | -18.55 | -37.64 | -21.24 | -41.14 | -46.98 | -450.51 | -52.13 | -454.62 | -- | -- | 0.0086 | -- | -- | 277.02 | 5.05 | -- | -- | -- |
Swedencare AB (publ) | 2.41bn | 71.50m | 9.04bn | 552.00 | 126.43 | 1.17 | 23.58 | 3.75 | 0.4505 | 0.4505 | 15.21 | 48.80 | 0.2412 | 2.35 | 9.52 | 4,966,461.00 | 0.7144 | 1.38 | 0.7361 | 1.43 | 55.64 | 55.34 | 2.96 | 5.10 | 1.82 | 2.21 | 0.1746 | 45.33 | 27.48 | 88.16 | -37.96 | 20.24 | 30.90 | -- |
BioGaia AB | 1.30bn | 371.25m | 11.98bn | 211.00 | 33.51 | 5.74 | 30.28 | 9.22 | 3.68 | 3.68 | 12.88 | 21.47 | 0.5414 | -- | -- | 6,192,767.00 | 15.46 | 15.47 | 16.82 | 16.93 | 73.32 | 73.30 | 28.55 | 27.70 | -- | -- | 0.00 | 104.42 | 17.44 | 11.81 | -2.25 | 11.20 | 29.27 | 28.10 |
Calliditas Therapeutics AB | 1.31bn | -524.82m | 12.29bn | 219.00 | -- | 92.11 | -- | 9.37 | -9.78 | -9.78 | 24.43 | 2.24 | 0.7541 | 3.16 | 8.97 | 6,723,169.00 | -30.19 | -26.46 | -38.05 | -30.27 | 95.01 | -- | -40.03 | -76.59 | 2.62 | -3.99 | 0.8943 | -- | 50.32 | -- | -13.08 | -- | -- | -- |
Vimian Group AB | 3.80bn | 90.12m | 17.14bn | 1.10k | 171.20 | 2.54 | 36.10 | 4.51 | 0.1936 | 0.1936 | 8.12 | 13.02 | 0.3354 | 2.83 | 5.69 | 3,457,184.00 | 0.867 | -- | 1.01 | -- | 47.48 | -- | 2.59 | -- | 1.19 | 2.81 | 0.3729 | -- | 17.92 | -- | 245.95 | -- | -- | -- |
Bonesupport Holding AB | 655.75m | 266.56m | 17.71bn | 121.00 | 66.60 | 31.28 | 63.90 | 27.00 | 4.05 | 4.05 | 9.96 | 8.61 | 1.19 | 0.657 | 6.36 | 6,245,276.00 | 48.22 | -9.08 | 61.41 | -11.28 | 92.01 | 90.25 | 40.65 | -11.65 | 2.42 | -- | 0.0282 | -- | 79.76 | 43.65 | 459.44 | -- | 18.39 | -- |
Holder | Shares | % Held |
---|---|---|
Fj�rde AP-fondenas of 31 Dec 2023 | 52.31m | 0.67% |
Ponderus Invest ABas of 31 Dec 2023 | 6.20m | 0.08% |